Literature DB >> 16675072

Structure- and oil type-based efficacy of emulsion adjuvants.

Theo Jansen1, Marij P M Hofmans, Marc J G Theelen, Frans Manders, Virgil E J C Schijns.   

Abstract

Oil-based emulsions are well-known immunopotentiators for inactivated, "killed" vaccines. We addressed the relationship between emulsion structure and levels of in vivo antibody formation to inactivated New Castle Disease virus (NDV) and Infectious Bronchitis virus (IBV) as antigens in 3-week-old chickens. The use of a polymeric emulsifier allowed for direct comparison of three types of emulsions, water-in-oil (W/O), oil-in-water (O/W) and W/O-in-water (W/O/W), while maintaining an identical content of components for each vehicle. They were prepared with either non-metabolizable, mineral oil or metabolizable, Miglyol 840. In addition, we assessed the inherent release capacity of each emulsion variant in vitro. Remarkably, we noted that W/O-type emulsions induced the best immune responses, while they released no antigen during 3 weeks. In general, mineral oil vaccines showed superior efficacy compared to Miglyol 840-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16675072     DOI: 10.1016/j.vaccine.2006.03.074

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

Authors:  Christopher B Fox; Susan L Baldwin; Malcolm S Duthie; Steven G Reed; Thomas S Vedvick
Journal:  Vaccine       Date:  2011-09-09       Impact factor: 3.641

2.  Nanocarrier vaccines for SARS-CoV-2.

Authors:  Jatin Machhi; Farah Shahjin; Srijanee Das; Milankumar Patel; Mai Mohamed Abdelmoaty; Jacob D Cohen; Preet Amol Singh; Ashish Baldi; Neha Bajwa; Raj Kumar; Lalit K Vora; Tapan A Patel; Maxim D Oleynikov; Dhruvkumar Soni; Pravin Yeapuri; Insiya Mukadam; Rajashree Chakraborty; Caroline G Saksena; Jonathan Herskovitz; Mahmudul Hasan; David Oupicky; Suvarthi Das; Ryan F Donnelly; Kenneth S Hettie; Linda Chang; Howard E Gendelman; Bhavesh D Kevadiya
Journal:  Adv Drug Deliv Rev       Date:  2021-01-09       Impact factor: 17.873

Review 3.  Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines.

Authors:  Huub F J Savelkoul; Valerie A Ferro; Marius M Strioga; Virgil E J C Schijns
Journal:  Vaccines (Basel)       Date:  2015-03-05

4.  Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy.

Authors:  Christopher B Fox; Lucien Barnes V; Tara Evers; James D Chesko; Thomas S Vedvick; Rhea N Coler; Steven G Reed; Susan L Baldwin
Journal:  Influenza Other Respir Viruses       Date:  2012-11-05       Impact factor: 4.380

Review 5.  Pickering Emulsions: Versatility of Colloidal Particles and Recent Applications.

Authors:  Hang Jiang; Yifeng Sheng; To Ngai
Journal:  Curr Opin Colloid Interface Sci       Date:  2020-05-08       Impact factor: 6.448

6.  Sunflower seed oil containing ginseng stem-leaf saponins (E515-D) is a safe adjuvant for Newcastle disease vaccine.

Authors:  L Yuan; Y Wang; Z Li; X Ma; X Cui; X Chi; W Xu; S Hu
Journal:  Poult Sci       Date:  2020-07-24       Impact factor: 3.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.